BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 27, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tysabri natalizumab: Post-marketing study data

In an update published on its website, Biogen Idec reported 6 confirmed cases of progressive multifocal leukoencephalopathy (PML) in patients receiving Tysabri monotherapy since the drug was relaunched in the U.S. and its first international approval in 2006. The latest case was reported on April 15 in...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >